Beyondspring Inc (BYSI)

$0.7344

-0.01

(-1.62%)▲

Live

Insights on Beyondspring Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 82.3% return, outperforming this stock by 105.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 160.7% return, outperforming this stock by 255.2%

Performance

  • $0.71
    $0.75
    $0.73
    downward going graph

    2.67%

    Downside

    Day's Volatility :5.89%

    Upside

    3.3%

    downward going graph
  • $0.54
    $3.45
    $0.73
    downward going graph

    25.75%

    Downside

    52 Weeks Volatility :84.29%

    Upside

    78.84%

    downward going graph

Returns

PeriodBeyondspring IncSector (Health Care)Index (Russel 2000)
3 Months
-41.22%
-1.3%
0.0%
6 Months
-33.35%
1.8%
-0.1%
1 Year
-23.23%
5.6%
5.6%
3 Years
-94.49%
24.9%
17.6%

Highlights

Market Capitalization
29.2M
Book Value
- $0.15
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.83
PEG Ratio
0.0
Wall Street Target Price
1.13
Profit Margin
0.0%
Operating Margin TTM
-2756.4%
Return On Assets TTM
-36.4%
Return On Equity TTM
-310.48%
Revenue TTM
1.4M
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
-0.1%
Gross Profit TTM
1.4M
EBITDA
-37.0M
Diluted Eps TTM
-0.83
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
-1.48
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Beyondspring Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
1
Hold
1
1
2
Sell
00
00
4

Analyst Forecast

What analysts predicted

Upside of 53.87%

Current $0.73
Target $1.13

Technicals Summary

Sell

Neutral

Buy

Beyondspring Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Beyondspring Inc
Beyondspring Inc
-17.06%
-33.35%
-23.23%
-94.49%
-97.14%
Moderna, Inc.
Moderna, Inc.
-13.55%
-32.61%
-15.08%
42.19%
439.09%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.53%
1.86%
20.63%
45.49%
111.7%
Novo Nordisk A/s
Novo Nordisk A/s
-3.85%
16.9%
82.33%
160.67%
293.13%
Seagen, Inc.
Seagen, Inc.
2.55%
4.95%
56.4%
11.14%
161.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.35%
12.18%
20.39%
30.41%
84.01%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Beyondspring Inc
Beyondspring Inc
NA
NA
0.0
0.0
-3.1
-0.36
0.0
-0.15
Moderna, Inc.
Moderna, Inc.
34.65
34.65
0.0
-3.45
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.08
22.08
9.01
41.9
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.05
43.05
2.03
1.64
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.16
27.16
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Beyondspring Inc
Beyondspring Inc
Buy
$29.2M
-97.14%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.8B
439.09%
34.65
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
111.7%
22.08
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$412.6B
293.13%
43.05
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.9B
161.51%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.0B
84.01%
27.16
35.4%

Institutional Holdings

  • BlackRock Inc

    0.63%

  • Hennion & Walsh Asset Management Inc

    0.25%

  • Millennium Management LLC

    0.24%

  • Group One Trading, LP

    0.16%

  • Two Sigma Investments LLC

    0.09%

  • State Street Corporation

    0.08%

Corporate Announcements

  • Beyondspring Inc Earnings

    Beyondspring Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers

Organization
Beyondspring Inc
Employees
73
CEO
Dr. Lan Huang
Industry
Health Technology

Discover More

FAQs